Popular Articles
Teeth Whitening Products

Number Of Abortion Procedures Continues To Decline In Minnesota And Wisconsin
The following summarizes news coverage of state abortion statistics in Minnesota and Wisconsin.~ Minnesota: The number of abortions performed in Minnesota decreased for the second consecutive year in 2008, according to an annual report from the state Department of Health, the Minneapolis Star Tribune reports. Except for a one-time increase in 2006, the number of abortions in Minnesota has trended downward since a peak in 1980, when 19,028 procedures were performed. The new report found that 12,948 abortions were performed in the state in 2008, a decrease of 895 from 2007. Women ages 20 to 24 accounted for about one-third of the procedures, the most among any age group. The number of procedures among teenagers continued a decline that began in the 1990s but had leveled off slightly earlier this decade, the report found. The report also found that less than one-third of women reported using contraception and about one in seven was married at the time of conception (Von Sternberg, Minneapolis Star Tribune, 7/1).~ Wisconsin: Wisconsin abortion providers performed 8,229 procedures in 2008, the lowest number since the state began collecting statistics in 1974, according to an annual report by the state Department of Health Services, the AP/Milwaukee Journal-Sentinel reports. The number of abortions has declined annually since 2003, when 10,557 procedures were performed. State law requires abortion providers to provide DHS with the data. According to the report, slightly more than half of abortions took place in the first eight weeks of pregnancy. Women who had never been married accounted for about three-fourths of all procedures. The report found that 12% of abortions occurred among women ages 35 and older; 34% were among women ages 20 to 24; 11% were among women ages 18 and 19; and 6% were among girls ages 15 to 17. The number of abortions among minors decreased from 551 in 2007 to 500 in 2008, with parents providing consent in 452 of those cases (Richmond, AP/Milwaukee Journal-Sentinel, 6/30).
generic viagra online
CareFirst BCBS Covers ENO Measurement For Diagnosis, Asthma Treatment
Apieron, Inc. said that CareFirst BlueCross BlueShield has adopted a positive coverage policy for the measurement of exhaled nitric oxide (eNO). The Medical Directors of CareFirst determined that the published, peer-reviewed evidence is sufficient to support benefit coverage for the treatment of asthma. The policy, effective July 20, 2009, states the measurement of exhaled nitric oxide is considered medically necessary in the management of asthma patients. CareFirst is the largest health care insurer in the Mid-Atlantic region, serving nearly 3.4 million members in Maryland, District of Columbia and portions of Virginia.
News of the day
Mental Illness Was One Of The Costliest Conditions Between 1996 To 2006
The number of Americans under care for depression and other mental illnesses nearly doubled between 1996 and 2006, and the overall cost of treating them jumped by nearly two-thirds, according to the latest News and Numbers from HHS" Agency for Healthcare Research and Quality.
Endocrinology

PolyMedix Receives United States Patent For Angiogenesis Inhibitor Compounds

PolyMedix, Inc. (OTCBB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, announced that the United States Patent and Trademark Office issued a patent assigned to PolyMedix relating to angiogenesis inhibitors. The patent, number 7,553,876, entitled "Polycationic Compounds and Uses Thereof," relates to therapeutic uses of PolyMedix compounds for inhibiting angiogenesis. Angiogenesis is a process involving the growth of new blood vessels. The abnormal growth of new blood vessels is associated with many diseases, including age-related macular degeneration (AMD), the most common form of blindness in the elderly, cancers, and inflammation. Inhibiting abnormal angiogenesis may be useful therapy for these conditions. Lucentis® and Macugen® are two products currently approved for treatment of AMD. PolyMedix"s angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor). "This is an exciting accomplishment for PolyMedix. This patent represents the first allowance from our applications relating to angiogenesis inhibition, and another compelling example of the efficiency and capabilities of our drug discovery approach," commented Nicholas Landekic, President and Chief Executive Officer. PolyMedix, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):